BEAMBeam Therapeutics Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 12389
Ticker: BEAM
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2020-02-06
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: BEAM

Detail

Enriched 2026-08-14 20:47

Market cap: $2,758,813,532.15
Shares outstanding (class): 103,287,665
Shares outstanding (weighted): 103,287,665
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 540
Location: CAMBRIDGE, MA
Homepage: https://www.beamtx.com
Description: Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Market cap and share counts drift.

Funds holding this security

114 funds · 116 positions · $457.96M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$77.41M	1.04%	3,248,626 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$73.80M	0.00%	3,097,050 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$55.73M	0.08%	2,338,510 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$53.22M	0.03%	2,233,453 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$29.76M	0.08%	1,248,869 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$26.23M	0.03%	1,100,832 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$26.07M	0.24%	1,093,992 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$18.51M	0.15%	776,898 NS	FIGI
T. Rowe Price Integrated U.S. Small-Cap Growth … T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$18.08M	0.22%	758,540 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$16.49M	0.20%	692,124 NS	FIGI
American Beacon ARK Transformational Innovation… AMERICAN BEACON FUNDS	—	$5.33M	3.40%	223,757 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$3.70M	0.08%	155,367 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$3.14M	0.00%	131,892 NS	FIGI
State Street(R) SPDR(R) S&P Kensho New Economie… SPDR SERIES TRUST	KOMP	$2.93M	0.12%	122,904 NS	FIGI
Large-Cap Growth Portfolio PACIFIC SELECT FUND	—	$2.91M	0.24%	122,052 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERBEAM
FIGI_COMPOSITEBBG00KXC8646
FIGI_SHARE_CLASSBBG00KXC8655
CIK0001745999
ISINUS07373V1052
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Beam Therapeutics is a biotech company developing gene editing therapies, classified under biological products.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.